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Hormonal evaluation of the reproductive potential of women 
in population based studies most often uses samples of blood 
(Ahrens et al., 2014; Jeppesen et al., 2013; Mumford et al., 
2012), urine (De Souza et al., 2010; Direito et al., 2013; Mc-
Connell et al., 2002; O’Connor et al., 2003), or saliva (Direito 
et al., 2013; Ellison et al., 2007; Kesner et al., 1992; Ziomkie-
wicz et al., 2008). These assessments are generally limited by 
participant training, compliance, and the cost of the assays. 
Indeed, the optimal method should yield good participant tol-
erance and compliance with sample collection while still pro-
viding reliable, sensitive, and specific information about the 
participants’ reproductive status (Kesner et al., 1992). 
In many cases, the use of the gold standard for repeated 
assessment of reproductive function, i.e., daily serum sam-
pling which involves invasive blood draws, is not feasible; 
therefore, the collection of daily urine samples is an advan-
tageous alternative due to its noninvasive and selfcollectable 
nature (Kesner et al., 1995). Daily collection of urine samples 
during a menstrual cycle or specified monitoring period pro-
vides information about reproductive hormone exposure and 
clinical endpoints of reproductive status, such as ovulation 
(Baird et al., 1995; Direito et al., 2013; Kassam et al., 1996; 
McConnell et al., 2002; O’Connor et al., 2006), pregnancy 
(Cate et al., 2013; Greene et al., 2013; Holman et al., 1998; 
O’Connor et al., 1998), and menstrual cycle status (De Souza 
et al., 2010; Direito et al., 2013; Mallinson et al., 2013b; Mum-
ford et al., 2012; O’Connor et al., 2011; Williams et al., 2010) 
in humans and non-human primates. Exposure to reproduc-
tive hormones has more recently been shown to be impor-
tant predictors of general health and disease risk. Measures 
of reproductive hormone exposure from daily urinary samples 
have been associated with cardiovascular function in amen-
orrheic exercising women, specifically endothelial dysfunc-
tion, bradycardia, low systolic blood pressure, reduced re-
gional blood flow, increased local vascular resistance, and 
an unfavorable lipid profile (O’Donnell et al., 2007; Ricken-
lund et al., 2005; Zeni Hoch et al., 2003). Further, reduced 
exposure to estrogen in amenorrheic exercising women, as 
assessed by daily urine sample collection, has been associ-
ated with increased concentrations of osteoprotegerin, an 
important regulator of bone resorption (West et al., 2009), 
and clinical measures of bone health (Mallinson et al., 2013a; 
Scheid et al., 2011). Risk of ovarian cancer (Parazzini et al., 
1989) and breast cancer (Kossman et al., 2011; Parazzini et 
al., 1993) have also been associated with exposure to repro-
ductive hormones. 
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Abstract
Objective — To determine if reducing the frequency of urinary sample collection from daily to 5, 3, or 2 days per week during a menstrual 
cycle or 28-day amenorrheic monitoring period provide accurate representations of the reproductive hormone metabolites estrone-
1-glucuronide (E1G) and pregnanediol glucuronide (PdG) exposure and mean concentrations. 
Methods  — Exercising women presenting with eumenorrhea or exercise-associated menstrual disturbances collected daily urine samples 
for the assessment of E1G and PdG concentrations. After enzyme immunoassay analysis of the daily samples, E1G and PdG data were 
systematically removed from each menstrual cycle or amenorrheic monitoring period to mimic three reduced collection frequencies, 
representing 5, 3, and 2 days per week. Exposure and mean concentration were calculated for both hormones and all four urinary col-
lection frequencies. 
Results  — E1G and PdG exposure and mean cycle concentrations derived from reduced collection frequencies were not different from daily 
collection (P>0.05), independent of whether menstrual cycles and monitoring periods were analyzed together or separately. Bland-Alt-
man analysis indicated acceptable agreement between each reduced collection frequency and daily collection. 
Conclusions — Compared with daily urinary collection, a reduced collection frequency of 5, 3, or 2 days each week provides accurate E1G and 
PdG profiles of collection periods of various lengths and types of menstrual function. Reduction of urinary sample collection frequency 
may enable researchers to reduce participant burden and costs, increase compliance, and study a wider range of study populations. 
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Unsupervised participants can easily collect urine sam-
ples, thus facilitating monitoring of ovarian function over 
extended time periods (Hall Moran et al., 2001). However, 
it has been noted that daily urine sample collection presents 
a substantial participant burden (Mumford et al., 2011). The 
substantial cost of time and participant burden can contrib-
ute to increased non-compliance and higher dropout rates 
(Mumford et al., 2011). Compliance with daily urinary sam-
ple collection is typically high in short-term studies (1–3 
months). The potential for reduced compliance increases 
over time (Mumford et al., 2011); however, specific data on 
participant compliance to urinary collection is scant in pub-
lications. For studies lasting between 1 and 3 months, com-
pliance to daily urinary sample collection is in the range 
of 92 to 97% (Kesner et al., 1992; Windham et al., 2002; 
Wright et al., 1992). For example, Kesner et al. (1992) re-
ported that during a time period of two complete menstrual 
cycles, 97% of all scheduled samples were collected. In the 
Women’s Reproductive Health Study, 93% of all daily urine 
samples were collected over the course of two consecutive 
menstrual cycles (Waller et al., 1998). 
In studies lasting between 5 and 12 months, compliance 
to urinary sample collection is more variable and somewhat 
lower, ranging between 50 and 100% (Kravitz et al., 2005; 
Liu et al., 2004; Santoro et al., 1996). For example, retro-
spective analysis of the Study of Women Across the Nation 
Daily Hormone substudy, only 680 of 848 eligible partici-
pants had collected 80% of the required samples (Kravitz 
et al., 2005). In the Semi-Conductor Health Study, where 
participants were asked to collect urinary samples daily for 
five cycles, only 57% of all cycles had fewer than 3 days of 
missing data in any 5-day rolling window (Liu et al., 2004). 
In our laboratory, the participants who completed 4 or more 
months of a 12-month study collected an average of 90% 
of the requested samples; however, individual compliance 
ranged from 61 to 100% (unpublished data). 
The design of any experiment needs to balance data 
quantity and quality while reducing participant burden and 
project cost and increasing compliance. To our knowledge, 
the only attempt to validate a reduced sampling frequency 
for use with urine specimens was conducted by O’Connor et 
al. (2006), who evaluated the specificity and sensitivity of 
reduced collection frequencies to determine the presence of 
ovulation with progesterone glucuronide based algorithms. 
The every other day reduced collection frequency accurately 
and precisely detected day of ovulation (O’Connor et al., 
2006). Thus, a reduced collection frequency could be use-
ful in conducting research in populations who may be hes-
itant to participate in research projects that involve daily 
urine sampling, such as children or adolescents, and may 
aid in collection of urinary samples in locations with limited 
cooling and storage capacity. In large-scale and long-term 
research studies, reduced collection frequencies would not 
only reduce project cost and participant burden but would 
also enable researchers to recruit from a larger demographic 
area due to the reduced need for storage. 
To reduce the burden of collecting daily urinary hormone 
specimens and reduce project costs, our goal was to evaluate 
if a reduction in the number of collection days from 7 days 
per week (i.e., daily sample collection) to 5 (i.e., weekday 
sample collection), 3 (i.e., Monday/Wednesday/ Friday), or 
2 (i.e., Monday/Thursday) days per week would provide an 
accurate representation of estrone-1-glucuronide (E1G) and 
pregnanediol glucuronide (PdG) exposure and mean con-
centration during an entire menstrual cycle/monitoring pe-
riod. We chose to evaluate the impact of reduced collection 
frequencies on E1G and PdG exposure and mean concentra-
tions because both measures are important predictors of 
bone health (Mallinson et al., 2013a; Scheid et al., 2011), 
cardiovascular health (O’Donnell et al., 2007; Rickenlund et 
al., 2005; Zeni Hoch et al., 2003), and ovarian (Parazzini et 
al., 1989) and breast cancer risk (Iversen et al., 2011; Koss-
man et al., 2011; Parazzini et al., 1993; Terry et al., 2005; 
Whelan et al., 1994). We also sought to evaluate if the va-
lidity of the reduced sample collection frequencies would be 
affected by cycle type (eumenorrheic or amenorrheic) or by 
variability of cycle lengths (20–45 days range or 26–36 days 
range). As such, the purpose of this analysis was to explore 
the average and individual agreement of daily urine sam-
ple collection versus sample collection for 5 days, 3 days, or 
2 days per week for the following variables: E1G exposure 
(area under the curve; AUC), E1G mean concentration, PdG 
exposure, and PdG mean concentration. We hypothesized 
that E1G and PdG cycle AUC and mean concentration would 
be similar when samples were collected daily versus 5 days, 
3 days, or 2 days per week for a 28-day monitoring period 
or a menstrual cycle with an intermenstrual interval rang-
ing from 20 to 45 days. 
Materials and Methods 
Experimental design 
This study utilizes menstrual cycle data from subjects par-
ticipating in a study conducted at two sites, University of 
Toronto (UT) and the Pennsylvania State University (PSU) 
over 8 years. Subjects included women with severe exer-
cise-associated menstrual disturbances (EAMD), includ-
ing oligomenorrhea (long and inconsistent menstrual cycle 
lengths of 36–90 days) and functional hypothalamic amen-
orrhea (the absence of menses for >90 days). The study 
also included a eumenorrheic exercising group (EU) that 
served as a control group. Concentrations of reproductive 
hormone metabolites were assessed in daily urinary sam-
ple collections. The study was approved by the Research 
Ethics Board at the UT and the Institutional Review Board 
at the PSU. All participants signed an approved informed 
consent document. 
Participants 
Women reporting regular menstrual cycles of 26 to 35 days 
for the previous 6 months before the study were recruited 
for the EU group, while women reporting no menses in the 
previous 3 months, or less than six cycles in the previous 12 
months were recruited for the EAMD group. Eligibility crite-
ria for the study included, (1) age 18 to 35 years; (2) weight 
stability (±2 kg) for at least 3 months; (3) body mass in-
dex (BMI) 16 to 25 kg/m2; (4) good health as determined by 
medical exam and no history of any serious medical condi-
tions; (5) no chronic illness, including hyperprolactinemia 
and thyroid disease; (6) not currently dieting; (7) no current 
clinical diagnosis of an eating disorder or psychiatric disor-
der; (8) non-smoking, (9) not taking any form of hormonal 
therapy for at least 6 months; (10) currently participating 
360 Allaway et al. ,  American Journal of Human Biology ,  27 (2015) 
in ≥2 h/week of purposeful exercise; (11) no history of a 
clinical diagnosis of polycystic ovarian syndrome (PCOS); 
(12) not pregnant, lactating, or planning a pregnancy; (13) 
no medication use that would alter metabolic or reproduc-
tive hormone concentrations; and (14) no other contraindi-
cations that would preclude participation in the study. 
Participant grouping categories 
Classification of participant menstrual status (eumenor-
rheic, oligomenorrheic, or amenorrheic) was based on self-
reported menstrual histories and menstrual calendars. Men-
strual status was confirmed by urinary concentrations of the 
reproductive hormone metabolites, E1G, PdG, and luteiniz-
ing hormone (LH). 
Demographic assessment 
Height (to the nearest 1.0 cm) and weight (to the nearest 
0.1 kg) were measured and participants completed ques-
tionnaires to assess medical history, exercise and menstrual 
history, eating behaviors and psychological health. A phys-
ical exam and blood sample were performed to determine 
overall health. 
Urinary collection procedures 
Participants in the EAMD group collected daily urinary sam-
ples for a 28-day monitoring period and EU participants col-
lected daily specimens for an entire menstrual cycle. The 
EAMD group initiated urinary collection on an arbitrary day 
in the study, while the EU group initiated urinary collection 
on day 1 or 2 of the menstrual cycle subsequent to demo-
graphic assessment. All participants utilized calendars to 
record menses and time of urine collection. All urine speci-
mens were labeled with calendar date, cycle/monitoring pe-
riod number, and cycle/monitoring period day. Participants 
stored urine specimens in their household freezers between 
drop offs at the laboratory. Frozen ice packs and insulated 
lunch packs were used to keep samples cold during trans-
port to the laboratory. In the laboratory urine samples were 
stored in a –20°C freezer until analyzed. 
Urinary measurement of E1G and PdG 
Microtiter plate competitive enzyme immunoassays (EIA) 
were used to measure E1G and PdG, as previously described 
(De Souza et al., 2010). The secretion of these estrogen and 
progesterone metabolites in the urine parallels serum con-
centrations of the parent hormones (Munro et al., 1991; 
O’Connor et al., 2003). Urinary concentrations of E1G and 
PdG were corrected for specific gravity, determined using a 
hand refractometer (NSG Precision Cells, Inc., Farmingdale, 
NY), to account for hydration status (Boeniger et al., 1993; 
Haddow et al., 1994; Miller et al., 2004). 
Selection of eligible cycles 
A flow chart is presented (Fig. 1) to describe the design of 
the study and the contribution of participants and cycles 
from each study site. A total of 116 participants and 572 cy-
cles/monitoring periods were evaluated for eligibility for 
this analysis. There were 63 amenorrheic participants with 
267 28-day monitoring periods and 79 eumenorrheic par-
ticipants with 305 menstrual cycles within the range of 
20 to 45 days. Menstrual cycle length was defined as the 
number of days from day 1 of menses to the day before the 
first day of the next menses. From this data set, 79 com-
plete menstrual cycles and 70 28-day monitoring periods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(contained no missing samples) that were collected during the 
12-month study were used in this analysis. In addition, 41 
menstrual cycles with no more than 3 missing days in the 
first 6 days of the cycle were also used. In these cases, con-
centrations of E1G and PdG for the missing days were es-
timated by averaging the concentrations from the day be-
fore and after the missing day. If the missing day was the 
first day of the cycle, days 2 to 4 of the cycle were aver-
aged to estimate the concentration for the missing day. 
Menstrual cycles included in the complete sample analysis 
were a combination of ovulatory (n = 23), luteal phase de-
fect (LPD; n = 43), and anovulatory (n = 54) cycle classifi-
cations. Classifications of menstrual cycles were completed 
from the original daily specimens and conducted to ensure 
inclusion of all types of menstrual cycles in the analysis. 
Specific hormonal criteria for classification of ovulatory, 
LPD, and anovulatory cycles has been described previ-
ously (De Souza et al., 2010). Sixty-one participants and 
their 382 menstrual cycles/monitoring periods were ex-
cluded from the analysis (Fig. 1). Monitoring periods (used 
for amenorrheic women) were excluded if there were any 
missing samples. Menstrual cycles (used for eumenorrheic 
and oligomenorrheic women) were excluded if there were 
more than 3 missing days in the first 6 collection days or 
any missing days beyond the first 6 days. Menstrual cycles 
were also excluded if the cycle length was outside the 20- 
to 45-day range included in this analysis. The UT site con-
tributed 27 participants and 90 menstrual cycles/monitor-
ing periods to this analysis while the PSU site contributed 
28 participants and 100 menstrual cycles/monitoring pe-
riods to this analysis (Fig. 1). 
Figure 1. Number of participants and menstrual cycles/monitoring 
periods which contributed to and were excluded from the current 
analysis. Data from participants recruited at two study sites, Uni-
versity of Toronto (UT) and the Pennsylvania State University (PSU), 
were included. Initially there were 572 menstrual cycles/28-day mon-
itoring periods from 116 participants evaluated for complete sample 
collection. Three hundred eighty-two menstrual cycles/monitoring 
periods from 61 participants were excluded from the analysis due to 
missing collection days. Included in the analysis were 190 menstrual 
cycles/monitoring periods from 55 participants, which included 90 
menstrual cycles/monitoring periods from 27 participants enrolled 
at the UT site and 100 menstrual cycles/monitoring periods from 28 
participants enrolled at the PSU site.
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Simulation of reduced number of sample collection days 
The daily samples per menstrual cycle/monitoring period 
(n = 190) collected by the participants were referenced to 
day of the menstrual cycle/monitoring period and collec-
tion calendar date. To determine if fewer days of urine col-
lection would provide accurate and precise data for E1G and 
PdG exposure and mean concentration during the menstrual 
cycle/monitoring period, E1G and PdG data were systemati-
cally removed from each menstrual cycle or 28-day monitor-
ing period to mimic a reduced frequency of sample collection 
for participants with 100% compliance to daily collection. 
The reduced sample collection frequencies were selected to 
reduce participant burden and represented three different 
collection frequencies as follows: 5 days of urine collection 
each week, 3 days of urine collection each week, and 2 days 
of urine collection each week. Specifically, for the simula-
tion of collecting five urinary samples per week, E1G and 
PdG data for Saturday and Sunday each week of the men-
strual cycle/monitoring period were systematically, leav-
ing only the E1G and PdG concentrations from the weekdays 
for analysis. For the simulation of collecting three urinary 
samples per week, E1G and PdG data were systematically 
removed for Tuesday, Thursday, Saturday, and Sunday each 
week of the menstrual cycle/monitoring period leaving E1G 
and PdG concentrations for Monday, Wednesday, and Fri-
day for the analysis. For simulation of collecting two uri-
nary samples per week, E1G and PdG data were systemat-
ically removed for Tuesday, Wednesday, Friday, Saturday, 
and Sunday each week of the menstrual cycle/monitoring 
period leaving only E1G and PdG concentrations for Mon-
day and Thursday for analysis. 
Urinary hormone assessment calculations 
E1G and PdG exposures across the menstrual cycle or mon-
itoring period were determined by calculating the AUC for 
daily, 5 days, 3 days, and 2 days per week collection frequen-
cies using Kaleidagraph Software (Synergy Software, Read-
ing. PA). Mean E1G and PdG concentrations across the cy-
cle or monitoring period for all collection frequencies were 
also calculated. 
Statistical analyses 
The data presented were obtained at two different locations, 
the UT and PSU, over 8 years. E1G and PdG data were ana-
lyzed as a merged group of eumenorrheic cycles of 20 to 45 
days in length and 28-day amenorrheic monitoring periods 
(complete sample analysis; n = 190). Subanalyses of eumen-
orrheic cycles of 26 to 36 days in length (which is the most 
common range of intermenstrual intervals among regularly 
menstruating women; n = 94) alone and 28-day amenor-
rheic monitoring periods (n = 70) alone. Data screening 
was conducted before statistical analysis in order to identify 
whether the data met the assumptions required by the spe-
cific statistical techniques in this analysis. Data screening in-
volved examination of variable distributions within each of 
the three analysis groupings for all four collection frequen-
cies (daily, 5 days, 3 days, and 2 days) and all four hormone 
variables (E1G AUC, PdG AUC, E1G mean, and PdG mean). 
All hormonal variables were found to be not normally dis-
tributed. However, logarithmic transformation did not im-
prove normality of these variables. In addition, logarithmic 
transformation was not considered as a practical approach 
for Bland-Altman analysis, as the limits of agreement (LOA) 
are expressed as multiples of the measured concentration 
following logarithmic transformation (Euser et al., 2008). 
All data are presented as means6SD, unless otherwise in-
dicated. Linear mixed model ANOVA was used to compare 
all ovarian steroid (E1G AUC, E1G mean, PdG AUC, or PdG 
mean) data between daily urinary collection and each re-
duced urinary collection frequency for the complete sam-
ples analysis and the eumenorrheic and amenorrheic sub-
analyses. Since the same individual provided multiple cycles 
and/or monitoring periods these data were considered to be 
of nested nature; therefore, the participant identifier was 
included as a random effect in the linear model. A signifi-
cance level of α = 0.05 was used to detect differences, and 
for multiple comparisons, a was adjusted using Bonferroni 
correction. Bland Altman analysis was performed to deter-
mine the 95% LOA and to identify potential mean and pro-
portional bias for both AUC and mean concentration (Bland 
and Altman, 1995). Errors were calculated as the difference 
between daily urinary collection data and each reduced uri-
nary collection data since daily urinary sample collection 
was regarded as the criterion method. For convenience, 
mean error and lower and upper LOA are also reported as 
percent of the average of daily and each reduced urinary col-
lection values. All analyses were conducted using R statisti-
cal software (Revolution Analytics, Palo Alto, CA). 
Results 
Complete sample analysis 
In total, there were 55 participants and 190 menstrual cy-
cles (20–45 days in length) and 28-day monitoring periods 
with complete data. There were 120 menstrual cycles and 70 
28-day amenorrheic monitoring periods. The participants 
were aged 22.6±64.3 years, weighed 57.0±6.6 kg, were 
164.3±6.6 cm tall, and had a BMI of 21.1±2.0 kg/m2. The 
average age at menarche was 13.2±1.6 years and the mean 
gynecologic age was 9.5±4.6 years. 
Mixed model analysis 
Composite graphs of the average E1G and PdG concentra-
tions, respectively, across the entire cycle/monitoring pe-
riod for daily, 5-day, 3-day, and 2-day collection frequencies 
are shown in Figure 2A, B. The average AUC and cycle mean 
concentration for each urinary collection frequency are dis-
played in inset bar graphs within the composite graphs and 
in Table 1. There were no significant differences detected 
between daily collection and each reduced collection fre-
quency (P > 0.99) with regard to E1G mean concentration; 
however, E1G AUC for 2 days per week collection was signif-
icantly lower when compared with E1G AUC for daily collec-
tion (P > 0.046). There were no significant differences de-
tected between daily collection and each reduced collection 
frequency (5 days, 3 days, or 2 days per week) with regard 
to PdG AUC (P > 0.050) or mean concentration (P > 0.99). 
Bland Altman analysis 
On average, the reduced urine collection frequencies for 
the complete sample analysis underestimate the daily E1G 
AUC by 1.4% for the 5-day collection frequency, 3.2% for 
the 3-day collection frequency, and by 8.2% for the 2- day 
362 Allaway et al. ,  American Journal of Human Biology ,  27 (2015) 
collection frequency. The 5-day collection frequency dem-
onstrated the lowest degree of underestimation and 2-day 
collection frequency demonstrated the greatest degree of 
underestimation when compared with daily sample collec-
tion. The E1G AUC for all reduced collection frequencies 
demonstrate good agreement with daily urine collection as 
indicated by the inclusion of zero in the 95% LOA for the 
Bland Altman analyses. The best agreement was observed 
with the 5-day collection frequency, indicated by the small-
est range for the 95% LOA (see Fig. 3A–C). A proportional 
bias was observed in all reduced collection frequencies 
(P < 0.010) indicating larger AUC values are, on average, un-
derestimated more than smaller AUC values in all reduced 
collection frequencies compared with daily urine collection 
(see Table 2). 
On average, reduced sample collection underestimated 
the daily PdG AUC by 0.6% for the 5-day collection fre-
quency, 2.9% for the 3-day collection frequency, and by 
10.8% for the 2-day collection frequency (see Fig. 3D–F 
and Table 3). The 5-day collection frequency demonstrated 
the lowest degree of underestimation of daily sampling, 
while the 2-day collection frequency demonstrated the 
greatest degree of underestimation. The PdG AUC for all re-
duced collection frequencies demonstrate good agreement 
with daily urine collection as indicated by the 95% LOA in-
cluding zero. The best agreement was observed with 5-day 
Figure 2. Composite graphs of urinary reproductive hormone excretion of E1G (A) and PdG (B) for eumenorrheic cycles of 20 to 45 days in 
length and 28-day amenorrheic monitoring periods for daily, 5-day/week, 3-day/week, and 2-day/week urinary collection frequencies. The 
inset bar graphs depict the cycle AUC and mean concentration for E1G and PdG for daily, 5-day/week, 3-day/week, and 2-day/week collec-
tion frequencies. Cycle day 1 represents the first day of menses. The data points for the central cycle/monitoring period days have an n 5 
190. Cycle/monitoring period days at the beginning and end of the composite graphs have a variable “n” due to the varying lengths of the 
cycles included in the sample. E1G, estrone-1-glucuronide; PdG, pregnanediol glucuronide; AUC, area under the curve. *Statistical differ-
ence (P < 0.05) between daily collection and 2 days per week collection frequency.
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collection frequency, indicated by the smallest range for the 
95% LOA. A proportional bias was not observed in the 5-day 
and 3-day collection frequencies (P = 0.10), while a propor-
tional bias was observed in the 2-day collection frequency 
(P < 0.000) indicating larger AUC values are, on average, 
underestimated more than smaller AUC values in the 2-day 
collection frequency compared with daily urine collection 
(see Table 3). 
Table 1. Reproductive steroid hormone metabolite parameters for the all cycles, eumenorrheic cycles only, and amenorrheic monitoring 
periods only analyses for all collection frequencies
                                                                                                                                Reduced collection frequency
  Daily  5-d/wk  3-d/wk  2-d/wk
  Mean±SE  Mean±SE  Mean±SE  Mean±SE
All cycles and monitoring periods (n = 190)
 E1G cycle mean AUC (ng × day/mL)  856.0±36.3  844.0±35.3  829.0±35.1  789.0.±34.2a
 E1G cycle mean concentration (ng/mL)  29.5±1.2  29.6±1.2  29.7±1.2  29.6±1.2
 PdG cycle mean AUC (mg × day/mL)  50.0±2.7  49.6±2.8  48.5±2.7  44.8±2.5b
 PdG cycle mean concentration (mg/mL)  1.7±0.1  1.8±0.1  1.8±0.1  1.7±0.1
Eumenorrheic cycles (n = 94)
 E1G cycle mean AUC (ng × day/mL)  1,037.5±50.7  1,027.5±50.5  1,014.7±50.7  972.5±49.2
 E1G cycle mean concentration (ng/mL)  35.7±1.7  35.9±1.7 36.2±1.7  36.2±1.8
 PdG cycle mean AUC (mg × day/mL)  68.4±4.2  68.4±4.2  67.0±4.1  62.2±4.0b
 PdG cycle mean concentration (mg/mL)  2.4±0.1  2.4±0.2  2.4±0.2  2.4±0.2
Amenorrheic periods (n = 70)
 E1G cycle mean AUC (ng × day/mL)  539.2±27.7  532.6±27.3  515.5±26.5  488.6±27.5
 E1G cycle mean concentration (ng/mL)  20.0±1.0  20.0±1.0  20.0±1.0  20.0±1.1
 PdG cycle mean AUC (mg × day/mL)  25.6±1.6  25.2±1.6  24.2±1.5  22.7±1.5
 PdG cycle mean concentration (mg/mL)  1.0±0.1  1.0±0.1  0.9±0.1  0.9±0.1
Reproductive steroid metabolite parameters include estrone-1-glucuonoide (E1G) and pregnanediol glucuronide (PdG) area under the 
curve (AUC) and mean concentration. d/wk, days per week. 
a. Significant differences (P<0.05) between the reduced collection frequency and daily collection frequency.
b. A trend for a difference (P<0.1) between the reduced collection frequency and daily collection frequency.
Figure 3. Bland Altman plots for all cycles 20 to 45 days in length and 28-day monitoring periods. The difference between daily and re-
duced collection frequencies are plotted against the mean of the daily and reduced collection frequency in the 190 paired measurements 
from the all cycles/monitoring periods analysis. The comparison of daily and 5 days/week collection frequency is in column 1, daily and 3 
days/week collection frequency is in column 2, and daily and 2 days/week collection frequency is in column 3. Differences between daily 
and the reduced collection frequencies for E1G AUC (A-C) and PdG AUC (D-F) are demonstrated.
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On average, daily E1G mean concentration was overes-
timated by 0.5% for the 5-day collection frequency, 0.8% 
for the 3-day collection frequency, and by 0.4% for the 2- 
day collection frequency (see Fig. 4A–C and Table 4). The 
2-day collection frequency demonstrated the lowest degree 
of overestimation of daily sampling, while the 3- day collec-
tion frequency demonstrated the greatest degree of overes-
timation. The E1G cycle mean concentration for all reduced 
collection frequencies demonstrate good agreement with 
daily urine collection as indicated by the 95% LOA includ-
ing zero. The best agreement was observed with the 5-day 
collection frequency, indicated by the smallest range for the 
95% LOA. A proportional bias was not observed in the 5-day 
and 3-day collection frequencies (P > 0.60), while a propor-
tional bias was observed in the 2-day collection frequency 
(P = 0.040) indicating greater cycle mean concentrations 
are, on average, overestimated more than smaller mean cy-
cle concentrations in 2-day collection frequency compared 
with daily collection (see Table 4). 
Daily PdG mean concentration was overestimated by 
2.2% for the 5-day collection frequency and 2.1% for the 
3-day collection frequency, while the 2-day collection fre-
quency underestimated the daily PdG mean concentration by 
0.2% (see Fig. 4D–F and Table 5). The 5-day collection fre-
quency demonstrated the greatest degree of overestimation 
of daily sample collection, while the 2-day collection fre-
quency demonstrated underestimation of daily sample col-
lection. The PdG cycle mean concentration for all reduced 
collection frequencies demonstrate good agreement with 
daily urine collection as indicated by the 95% LOA includ-
ing zero. The best agreement was observed with the 5-day 
collection frequency, indicated by the smallest range for the 
95% LOA. A proportional bias was observed in the 5-day and 
3-day collection frequencies (P < 0.010) indicating greater 
cycle mean concentrations are, on average, overestimated 
compared with daily urine collection, while a trend toward 
a proportional bias was observed in the 2-day collection fre-
quency (P = 0.060; see Table 5). 
Subanalysis of eumenorrheic cycles 
A subanalysis of eumenorrheic menstrual cycles of 26 to 36 
days in length included 31 participants and 94 menstrual cy-
cles with complete data. This subanalysis included anovu-
latory (n = 14), LPD (n = 31), and ovulatory (n = 49) men-
strual cycles, which were classified using daily collection 
frequency hormonal measurements. The participants were 
Table 2. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of E1G AUC
                                                                                                                              Bland-Altman analysis
 Mean       Lower limit  Upper limit       Proportional 
 difference of agreement       of agreement  bias
Method  (ng x day/mL)  %  (ng x day/mL)  %  (ng x day/mL)  % 
All cycles and monitoring periods (n = 190)
 Daily vs. 5-d/wk  12.0  1.4  -133.8  -15.7  157.9  18.6 0.0132
 Daily vs. 3-d/wk  27.2  3.2 -141.8  -16.8  196.2  23.3  0.0140
 Daily vs. 2-d/wk  67.0  8.2  -136.8  -16.6  270.8  32.9  0.0001
Eumenorrheic cycles (n = 94)
 Daily vs. 5-d/wk  10.0  1.0  -106.1  -10.3  126.1  12.2  0.6988
 Daily vs. 3-d/wk  22.7  2.2  -122.1  -11.9  167.5  16.3  0.9908
 Daily vs. 2-d/wk  65.0  6.5  -127.4  -12.7  257.3  25.6  0.1528
Amenorrheic periods (n = 70)
 Daily vs. 5-d/wk  6.6  1.2  -65.9  -12.3  79.1  14.8  0.4515
 Daily vs. 3-d/wk  23.7  4.5  -60.4  -11.5  107.8  20.4  0.0405
 Daily vs. 2-d/wk  50.6  9.8  -84.1  -16.4  185.2  36.0  0.8165
E1G, estrone-1-glucuronide; AUC, area under the curve; d/wk, days per week.
Table 3. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of PdG AUC
                                                                                                                               Bland-Altman analysis
 Mean       Lower limit  Upper limit       Proportional 
 difference of agreement       of agreement  bias
Method  (mg x day/mL)  %  (mg x day/mL)  %  (mg x day/mL)  %  bias
All cycles and monitoring periods (n = 190)
 Daily vs. 5-d/wk  0.3  0.6  -8.8  -17.7  9.5  19.0  0.1819
 Daily vs. 3-d/wk  1.4  2.9  -12.7  -25.8  15.6  31.7  0.4675
 Daily vs. 2-d/wk  5.1  10.8  -12.4  -26.3  22.7  47.9  0.0000
Eumenorrheic cycles (n = 94)
 Daily vs. 5-d/wk  0.1  0.1  -12.1  -17.6  12.2  17.8  0.5247
 Daily vs. 3-d/wk  1.4  2.0  -17.8  -26.3  20.5  30.3  0.3789
 Daily vs. 2-d/wk  6.2  9.6  -15.8  -24.3  28.3  43.4  0.0541
Amenorrheic periods (n = 70)
 Daily vs. 5-d/wk  0.4  1.7  -3.5  -13.8  4.3  17.1  0.1814
 Daily vs. 3-d/wk  1.4  5.6  -3.7  -15.0  6.5  26.3  0.0016
 Daily vs. 2-d/wk  2.8  11.8  -4.4  -18.2  10.1  41.8 0.0314
PdG, pregnanediol glucuronide; AUC, area under the curve; d/wk, days per week.
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aged 24±4.5 years, weighed 57.1±6.0 kg, were 164.5±6.5 cm 
tall, and had a BMI of 21.1±1.7 kg/m2. The average age at 
menarche was 12.5±.3 years and the mean gynecologic age 
was 11.5±4.3 years. 
Mixed model analysis 
Composite graphs of the average E1G and PdG concentra-
tions, respectively, across the entire cycle for daily, 5- day, 
3-day, and 2-day collection frequencies are shown in Fig-
ure 5A,B. The classic characteristics of ovulatory cycles, 
i.e. the mid-cycle E1G peak and luteal phase PdG peak, are 
evident. The average AUC and cycle mean concentration 
for each urinary collection frequency are displayed in in-
set bar graphs within the composite graphs and in Table 
1. There were no significant differences detected between 
daily collection and each reduced collection frequency (5 
days, 3 days, or 2 days per week) with regard to E1G AUC 
(P > 0.46) or mean concentration (P > 0.99). There were 
no significant differences detected between daily collection 
and each reduced collection frequency (5 days, 3 days, or 2 
days per week) with regard to PdG AUC (P > 0.27) or mean 
concentration (P > 0.99). 
Figure 4. Bland Altman plots for all cycles 20 to 45 days in length and 28-day monitoring periods. The difference between daily and re-
duced collection frequencies are plotted against the mean of the daily and reduced collection frequency in the 190 paired measurements 
from the all cycles/monitoring periods analysis. The comparison of daily and 5 days/week collection frequency is in column 1, daily and 3 
days/week collection frequency is in column 2, and daily and 2 days/week collection frequency is in column 3. Differences between daily 
and the reduced collection frequencies for E1G mean (A–C) and PdG mean (D–F) are demonstrated.
Table 4. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of E1G mean
                                                                                                                             Bland-Altman analysis
         Mean                        Lower limit                    Upper limit                          Proportional 
                                                  difference                   of agreement                 of agreement                               bias
Method                                                                (ng/mL)  %             (ng/mL)       %   (ng/mL)  %  
All cycles and monitoring periods (n = 190)
 Daily vs. 5-d/wk  –0.1  -0.5  -3.8  -13.0  3.6  12.1  0.9569
 Daily vs. 3-d/wk  -0.2  -0.8  -5.2  -17.7  4.8  16.1  0.5725
 Daily vs. 2-d/wk  -0.1  -0.4  -6.7  -22.6  6.4  21.8  0.0352
Eumenorrheic cycles (n = 94)
 Daily vs. 5-d/wk  -0.3  -0.8  -3.8  -10.6  3.3  9.1  0.4931
 Daily vs. 3-d/wk  -0.5  -1.4  -5.3  -14.7  4.2  11.8  0.1312
 Daily vs. 2-d/wk  -0.5  -1.5  -7.1  -19.7  6.0  16.7  0.0067
Amenorrheic periods (n = 70)
 Daily vs. 5-d/wk  0.0  0.0  -1.8  -9.1  1.8  9.1  0.5498
 Daily vs. 3-d/wk  0.0  -0.2  -2.9  -14.3  2.8  14.0  0.8204
 Daily vs. 2-d/wk  0.0  -0.2  -5.7  -28.7  5.7  28.4  0.0066
E1G, estrone-1-glucuronide; d/wk, days per week.
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Bland Altman analysis 
The reduced collection frequencies for eumenorrheic cycles 
of 26 to 36 days in length, on average, underestimate the 
daily E1G AUC as shown in Table 2. The E1G AUC for all re-
duced collection frequencies demonstrate good agreement 
with daily urine collection as indicated by the 95% LOA in-
cluding zero. The best agreement is observed with 5-day 
collection, indicated by the tighter range for the 95% LOA. 
A proportional bias was not observed in any of the reduced 
collection frequencies (P > 0.20), as shown in Table 2. As 
shown in Table 3, the reduced collection frequencies for eu-
menorrheic cycles alone, on average, underestimated the 
daily PdG AUC. The smallest range for the 95% LOA was ob-
served in the 5-day collection frequency indicating the best 
agreement with daily sample collection. A proportional bias 
was not observed in any of the reduced collection frequen-
cies (P > 0.050), as shown in Table 3. 
Reduction of the collection frequency for eumenor-
rheic cycles of 26 to 36 days in length, on average, over-
estimated the E1G mean concentration as shown in Table 
4. The 5-day collection frequency demonstrated the low-
est degree of overestimation of E1G cycle mean concentra-
tion, while the 2-day collection frequency demonstrated the 
greatest degree of overestimation. A proportional bias was 
not observed in the 5-day and 3-day collection frequencies 
(P > 0.10); however, a proportional bias was observed in the 
2-day collection frequency (P = 0.007), as shown in Table 
4. On average, the daily PdG cycle mean concentration was 
overestimated by the reduced collection frequencies for eu-
menorrheic cycles of 26 to 36 days in length, as shown in Ta-
ble 5. The best agreement was observed with 5-day collec-
tion frequency, indicated by the smaller range for the 95% 
LOA. A proportional bias was not observed in the 3-day col-
lection frequency (P = 0.20); however, a proportional bias 
was observed in the 5-day and 2-day collection frequencies 
(P < 0.030), as shown in Table 5. 
Subanalysis of amenorrheic monitoring periods 
In a subanalysis of amenorrheic monitoring periods of 28 
days there were 19 participants and 70 monitoring periods 
with complete data. The participants were aged 21.2±3.5 
years, weighed 57.3±7.8 kg, were 165.1±.0 cm tall, and had 
a BMI of 21.1±2.4 kg/m2. The average age at menarche was 
14.1±1.4 years and the mean gynecologic age was 7±3.9 
years. 
Mixed model analysis 
Composite graphs of the average E1G and PdG concentra-
tions, respectively, across the entire monitoring period for 
daily, 5-day, 3-day, and 2-day collection frequencies are 
shown in Figure 6A,B. The chronic suppression of E1G and 
PdG that is characteristic of reproductive hormone con-
centrations among amenorrheic women is clearly evident. 
Within the inset bar graphs and Table 1, the average AUC 
and cycle mean concentrations are displayed for each fre-
quency of urinary collection. There were no significant dif-
ferences detected between daily collection and each reduced 
collection frequency (5 days, 3 days, or 2 days per week) 
with regard to E1G AUC (P > 0.12) or mean concentration (P 
> 0.99). There were no significant differences detected be-
tween daily collection and each reduced collection frequency 
(5 days, 3 days, or 2 days per week) with regard to PdG AUC 
(P > 0.080) or mean concentration (P > 0.99). 
Bland Altman analysis 
In amenorrheic 28-day monitoring periods daily sample col-
lection E1G AUC was, on average, underestimated by the re-
duced collection frequencies (see Table 2). The E1G AUC for 
all reduced collection frequencies demonstrate good agree-
ment with daily urine collection as indicated by the 95% 
LOA including zero. The best agreement was observed with 
the 5-day sample collection frequency, indicated by the 
smaller range for the 95% LOA. A proportional bias was 
not observed in the 5-day and 2-day collection frequen-
cies (P > 0.20), but a proportional bias was observed in the 
3-day collection frequency (P 5 0.04; see Table 2). Daily PdG 
AUC was, on average, underestimated by the reduced col-
lection frequencies for 28-day monitoring periods (see Ta-
ble 3). The smallest range for the 95% LOA was observed 
in the 5-day collection frequency, indicating the best agree-
ment with daily sample collection. A proportional bias was 
not observed in the 5- day collection frequency (P > 0.20); 
however, a proportional bias was observed in the 3-day and 
2-day collection frequencies (P < 0.030; see Table 3). 
Table 5. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of PdG mean
                                                                                                                            Bland-Altman analysis
         Mean                        Lower limit                    Upper limit                          Proportional 
                                                  difference                   of agreement                 of agreement                               bias
Method                                                                (ng/mL)  %             (ng/mL)       %   (ng/mL)  %  
All cycles and monitoring periods (n 5 190)
 Daily vs. 5-d/wk  0.0  –2.2  –0.3  –16.5  0.2  12.2  0.0000
 Daily vs. 3-d/wk  0.0  –2.1  –0.5  –29.0  0.4  24.7  0.0115
 Daily vs. 2-d/wk  0.0  0.2  –0.6  –37.3  0.7  37.7  0.0635
Eumenorrheic cycles (n = 94)
 Daily vs. 5-d/wk  –0.1  –2.9  –.4  –16.3  0.3  10.6  0.0004
 Daily vs. 3-d/wk  –0.1  –3.1  –.7  –29.2  0.6  23.1  0.2167
 Daily vs. 2-d/wk  0.0  –1.3  –.9  –36.2  0.8  33.5 0.0296
Amenorrheic periods (n = 70)
 Daily vs. 5-d/wk  0.0  –0.6  –0.1  –11.8  0.1  10.5  0.2336
 Daily vs. 3-d/wk  0.0  0.7  –.2  –16.9  0.2  18.3  0.3317
 Daily vs. 2-d/wk  0.0  1.6  –.2  –26.3  0.3  29.4  0.4256
PdG, pregnanediol glucuronide; d/wk, days per week.
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The 5-day collection frequency for 28-day monitoring pe-
riods, on average, estimated the daily E1G cycle mean con-
centration, while 3-day and 2-day collection frequencies 
overestimated E1G cycle mean concentration (see Table 4). 
The calculated E1G cycle mean concentration for all 28-day 
monitoring periods and reduced collection frequencies dem-
onstrate good agreement with daily urine collection as in-
dicated by the 95% LOA including zero. A proportional bias 
was not observed in the 5-day and 3-day collection frequen-
cies (P > 0.50); whereas, a proportional bias was observed 
in the 2-day collection frequency (P < 0.007; see Table 4). 
The 3-day and 2-day collection frequencies for 28-day mon-
itoring periods underestimate the daily PdG cycle mean con-
centration, on average, while the 5-day collection frequency 
overestimated the PdG mean cycle concentration (see Table 
5). The best agreement is observed with 5-day collection 
frequency, indicated by the smaller range for the 95% LOA. 
A proportional bias was not observed in any of the reduced 
collection frequencies (P > 0.20; see Table 5). 
Discussion 
The present study was designed to assess the level of agree-
ment between reduced urinary collection frequencies (5 
days, 3 days, or 2 days per week) and the urinary gold stan-
dard of daily specimen collection in a sample of exercis-
ing eumenorrheic and amenorrheic women and in specific 
subpopulations of eumenorrheic and amenorrheic exer-
cising women. This report is the first to provide detailed 
information on the accuracy and precision of quantifying 
Figure 5. Composite graphs of urinary reproductive hormone excretion of E1G (A) and PdG (B) for eumenorrheic cycles of 26 to 36 days in 
length for daily, 5-day/week, 3-day/week, and 2-day/week urinary collection frequencies. The inset bar graphs depict the cycle AUC and 
mean concentration for daily, 5-day/week, 3-day/week, and 2-day/week collection frequencies. Cycle day 1 is the first day of menses. The 
data points for the central cycle/monitoring period days have an n 5 94. Cycle/monitoring period days at the beginning and end of the com-
posite graph have a variable “n” due to the varying lengths of the cycles included in the subsample. E1G, estrone-1-glucuronide; PdG, preg-
nanediol glucuronide; AUC, area under the curve.
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reproductive hormone exposure using a reduced sampling 
schedule. This report supports and builds upon the work of 
O’Connor et al. (2006), which tested the presence and day 
of ovulation during reduced urinary collection frequencies. 
All comparisons between daily collection and each of the 
reduced collection frequencies (5 days, 3 days, or 2 days 
per week) for the average AUC and mean concentration for 
both E1G and PdG were not different when eumenorrheic cy-
cles and amenorrheic monitoring periods were analyzed to-
gether and when analyzed separately; however, a difference 
was observed between daily collection and 2 days per week 
collection frequency with regard to the average E1G AUC in 
the complete cycle analysis. In general the 5-day collection 
frequency demonstrated the best agreement with daily sam-
ple collection in all three analyses. The 3-day and 2-day col-
lection frequencies also showed good agreement with daily 
sample collection in all three analyses of exercising women. 
The LOA for individual AUC and mean concentrations, how-
ever, appeared to increase with reduced sample collection 
frequencies. Depending on the required level of accuracy 
and precision, researches may choose to use varying sam-
pling frequencies. The present analysis is the first to quan-
tify mean error as well as individual agreement for urinary 
reproductive hormones. 
The Bland Altman analysis was used to compare the 
daily and reduced collection frequencies (Bland and Altman, 
Figure 6. Composite graphs of urinary reproductive hormone excretion of E1G (A) and PdG (B) for 28 day amenorrheic monitoring peri-
ods for daily, 5-day/week, 3-day/week, and 2-day/week urinary collection frequencies. The inset bar graphs depict the monitoring period 
AUC and mean concentration for daily, 5-day/week, 3-day/week, and 2-day/week collection frequencies. Monitoring period day 1 is the 
first day of sample collection. The data points for the monitoring period days have an n = 70. E1G, estrone-1-glucuronide; PdG, pregnane-
diol glucuronide; AUC, area under the curve.
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1986). This technique was used to assess the agreement be-
tween reduced collection frequencies (5 days, 3 days, or 2 
days each week) and daily sample collection. If the differ-
ences between the reduced collection frequencies and daily 
collection are not large enough to change the interpretation 
of the research findings, daily collection could be replaced by 
the reduced collection frequencies or the collection frequen-
cies could be used interchangeably. Though there were small 
over- or underestimations of the AUC and mean concentra-
tions observed in the Bland Altman analysis, good agreement 
among the reduced collection frequencies compared with 
daily collection frequency was observed according to the in-
clusion of zero in the Bland Altman LOA. The Bland Altman 
analysis indicated that the AUC for E1G and PdG from re-
duced urinary collection frequencies were within 9.8% and 
11.8% of the daily measures, respectively, in the complete 
samples analysis and separate eumenorrheic and amenor-
rheic analyses. The AUC percent differences would have en-
abled O’Donnell et al. (2007) and West et al. (2009) to de-
tect the observed 33 to 98% differences in E1G AUC between 
sedentary and exercising eumenorrheic women and exer-
cising amenorrheic women. The mean concentrations for 
E1G and PdG from reduced urinary collection frequencies 
were within 1.5% and 3.1% of the daily measures, respec-
tively, for all three analyses. Differences in mean concen-
trations between ethnicities, which have been reported to 
lie between 1.0 and 22.3% (E1G) and 3.0 and 31.7% (PdG) 
(Santoro et al., 2004), would have been observed using 2 
days per week as collection frequency. However, observ-
ing subtle differences of 1 to 5% in E1G and PdG AUC, as 
reported between sedentary and exercising eumenorrheic 
women (O’Donnell et al., 2007; West et al., 2009) would re-
quire the urinary collection frequency to be no fewer than 
3 days per week (3.2% for E1G and 2.9% for PdG mean per-
cent difference). Use of reduced urinary collection frequen-
cies as few as 2 days per week to assess group differences 
in cycle AUC and mean concentration provides comparable 
values to daily urinary collection. Thus, the use of reduced 
collection frequencies would still allow detection of differ-
ences between experimental groups. 
In a study by Mumford et al. (2012) 8 serum samples 
were collected during biologically relevant windows timed 
to a standardized 28-day menstrual cycle. The serum sam-
ples were utilized to assess the exposure to reproductive 
hormones in women with short (<26 days), normal (26–35 
days), and long (>35 days) menstrual cycle lengths. Unfortu-
nately, the authors did not conduct a comparison of the eight 
samples to daily sampling, but the AUC values presented by 
Mumford et al. (2012) demonstrated a high standard error 
indicating eight samples per menstrual cycle to be too large 
a reduction in sample collection. The authors commented 
that collecting only eight serum samples throughout the 
menstrual cycle reduced the generalizability of their find-
ings in women with longer and more irregular cycles (Mum-
ford et al., 2012). The basic shape of the E1G and PdG curves 
across the menstrual cycles in our analysis indicate that re-
ducing the urinary collection frequency as low as eight sam-
ples per cycle (2 days per week in a 28-day menstrual cycle 
or monitoring period) increases the likelihood of missing the 
peak hormonal concentrations, thus greatly altering the AUC 
and mean concentration calculations. In our analysis a re-
duced collection frequency of less than 5 days per week was 
associated with an increased range for the LOA due to the 
potential of missing peak hormonal concentrations, which 
may also compromise the use of reduced collection frequen-
cies in studies evaluating individual subjects and clinical 
outcomes, such as day of ovulation. 
The shape and timing of the peaks of E1G and PdG greatly 
affect the determination of exposure and cycle mean concen-
tration. For example, the E1G peak is generally narrow and 
rises quickly to a peak, while the PdG peak is a broad curve. 
Hence, the narrow peak for E1G is more likely to be missed 
by a reduced sample collection frequency compared with the 
peak of a broad curve, like PdG. Differences in capture of the 
E1G and PdG peaks are shown in the composite graphs (Figs. 
2, 5, and 6). Figure 5 shows that the broad PdG peak was not 
influenced by the reduced collection frequencies; however, 
the shape of the E1G peak is varied, though not visually dif-
ferent, between the reduced collection frequencies and daily 
collection hormone profile. Within a group analysis a pro-
portion of the narrow peaks would be captured with the re-
duced collection frequencies, thus the increased LOA; how-
ever, when analyzing a cycle from an individual participant 
it is highly likely the E1G peak concentration would have oc-
curred on a non-sample collection day. When evaluating in-
dividual cycles for a case report, as seen with Mallinson et 
al. (2013), a reduction in the collection frequency as low as 
2 days per week would not influence the characterization 
of the cycle via hormonal exposure in a participant who has 
had amenorrhea for a long period of time. In a participant 
who had amenorrhea for a short period of time a reduction 
in sample collection to 2 days a week would underestimate 
the exposure of the participant to reproductive hormones 
due to higher variations in monitoring period peaks of E1G 
and PdG across a year (Mallinson et al., 2013b). 
Urinary samples are self-collectable, noninvasive, can be 
easily stored and transported, and have been shown to tol-
erate a wide variety of non-perfect experimental conditions 
in the field (O’Connor et al., 2006; Kesner et al., 1995). Ini-
tially it was assumed that daily samples could be collected 
for prolonged periods of time with a high degree of compli-
ance, however, many recent studies have shown compliance 
to be highly variable depending on study length (Kesner et 
al., 1992; Kravitz et al., 2005; Liu et al., 2004; Santoro et 
al., 1996; Waller et al., 1998; Wright et al., 1992). The level 
of compliance to sample collection may be due to personal 
or housemate comfort level with storage of specimens or 
ability to store samples when away from the primary resi-
dential address. Participants in early studies which evalu-
ated perceptions of urinary sample collection reported that 
the benefits of increased knowledge about their body out-
weighed the uncomfortable nature of urine collection (Wil-
cox et al., 1987; Wright et al., 1992). According to Wright et 
al. (1992), urine collection was one of the least objection-
able of the eight methods used to assess reproductive func-
tion (transvaginal ultrasound, basal body temperature, sali-
vary electrical resistance, blood sampling, salivary samples, 
vaginal mucus electrical resistance, and manual cervical mu-
cus consistency). The study by Wright et al. (1992) was one 
of the first to assess the attitudes of the general popula-
tion, instead of nurses, to reproductive hormone collection 
methods. Anecdotal evidence from our laboratory has indi-
cated that participant travel over weekends and for vaca-
tions lead to large gaps in sample collection and decreased 
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compliance, thus the reduced collection frequencies evalu-
ated in this article provided the participants with weekends 
free from sample collection. In fact, for this analysis we ex-
cluded 67% of available cycles due to reduced compliance. 
In studies of long duration it is unavoidable to have partic-
ipants run into vacation time such as Thanksgiving, family 
summer holidays, or winter break, when reduced compli-
ance to sample collection is more likely to occur. 
One limitation of the present analysis was the restriction 
of the data set to only include subjects who were 100% com-
pliant to the reduced collection frequencies. The presence of 
missed collection days within the reduced sample collection 
frequencies would decrease the accuracy of the urinary re-
productive hormone metabolite profile across the menstrual 
cycle or monitoring period. Reduced collection frequency 
strategies still require the use of a valid menstrual cycle cal-
endar in order to create an accurate presentation of the hor-
monal profile. Not all urinary collections for eumenorrheic 
cycles will begin on the first day of the menstrual cycle nor 
will the final collection always be on the last day of the men-
strual cycle. Another limitation of the study was that we did 
not evaluate clinical reproductive outcomes in this analysis; 
however, such outcomes are integral in the usefulness of re-
duced collection frequencies. Future studies should evaluate 
the validity of the reduced collection frequencies evaluated 
in this article in detecting luteal sufficiency and assessing 
this strategy in an independent sample. 
The strengths of this analysis are that there were a large 
number of cycles included, individual participants provided 
multiple cycles, and the cycles used for reducing the collec-
tion frequency were based on menstrual cycles, and 28-day 
monitoring periods that had all samples collected. In the 
data set, there are near equal numbers of short, normal, 
and long menstrual cycles in the eumenorrheic participant 
cycles and 28-day monitoring periods. Within our eumen-
orrheic cycles we intentionally included all cycle classifica-
tions (LPD, anovulatory, and ovulatory cycles) to show that 
even with cycles of highly variable hormone levels the re-
duced collection frequencies continue to have good agree-
ment with daily urinary sample collection. 
Though daily urinary collection is the most accurate re-
flection of reproductive hormone production when using uri-
nary analysis, our results demonstrate that accurate E1G 
and PdG profiles of menstrual cycles of various lengths (20–
45 days) and types (eumenorrheic and amenorrheic) can 
be measured with reduced urinary collection frequencies. 
This work supports and builds on the work of O’Connor et 
al. (2006) demonstrating that a reduced sampling schedule 
can provide useful and accurate information in a manner 
that is comparable to that obtained from daily sampling of 
urine regarding ovarian hormone exposure and mean con-
centrations. The accuracy in quantifying exposure allows re-
duced collection frequency strategies to be utilized in under 
researched populations and in less developed regions around 
the world, where the capacity to store samples in a cold en-
vironment may be limited. The reduced collection frequen-
cies produced composite E1G and PdG profiles for an entire 
cycle or monitoring period that were similar to the com-
posite graphs of daily urinary collection. We have shown 
that daily ovarian steroid levels are not necessarily required 
to quantify AUC or mean values E1G or PdG across the en-
tire menstrual cycle or monitoring period when conducting 
group examinations for the assessment of disease risk, such 
as osteoporosis, endothelial dysfunction, ovarian cancer, 
and breast cancer, in large populations. Further research is 
needed to evaluate whether clinical outcomes, such as lu-
teal sufficiency, are possible to determine through these spe-
cific reduced collection frequencies. We suggest reducing the 
urinary collection frequency in an effort to reduce the par-
ticipant burden, increase compliance, and decrease project 
costs, depending on the accuracy and precision required to 
answer the reproductive questions of interest. 
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